AstraZeneca Rating Reiterated by Barclays (AZN)
AstraZeneca (LON:AZN)‘s stock had its “equal weight” rating reiterated by equities researchers at Barclays in a research report issued on Friday, AmericanBankingNews.com reports. They currently have a GBX 3,300 ($54.38) target price on the stock. Barclays’ target price would indicate a potential downside of 14.82% from the company’s current price.
A number of other analysts have also recently weighed in on AZN. Analysts at Panmure Gordon raised their price target on shares of AstraZeneca from GBX 3,200 ($52.74) to GBX 3,500 ($57.68) in a research note to investors on Thursday. They now have a “sell” rating on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,220 ($53.07) price target on the stock. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 4,600 ($75.81) price target on the stock. Twelve analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 3,340.28 ($55.05).
Shares of AstraZeneca (LON:AZN) opened at 3875.00 on Friday. AstraZeneca has a one year low of GBX 2895.00 and a one year high of GBX 3845.00. The stock has a 50-day moving average of GBX 3568. and a 200-day moving average of GBX 3323.. The company’s market cap is £48.554 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.